December 06, 2022
“We were able to develop a machine learning model that had decent accuracy…in predicting which patients would have an additional stone event and which patients wouldn't,” says Kevin Shee, MD, PhD.
November 30, 2022
“What we found is that the use of these drugs and novel hormonal therapies and chemotherapy in the metastatic castration-sensitive setting was relatively low,” said Stephen J. Freedland, MD.
November 28, 2022
Dr. Goldberg discusses his findings on the rates of shared decision-making and PSA testing, which were presented at the NSAUA meeting in Charlotte, North Carolina.
November 18, 2022
“When we think about all the other office-based procedures we do, such as transrectal biopsies and vasectomies that are done in-clinic, I think that technology can play a big role in these," says Dr. Myrga.
November 07, 2022
“We do know that for these specific racial minorities, more time and more tools need to be invested in order to have both the rates of PSA discussion and PSA testing equal to those that White men have,” says Hanan Goldberg, MD, MSc.
November 02, 2022
“It didn't happen overnight. The way we built the program was an iterative process,” says Shubham Gupta, MD.
“What was found in the sub stratification study was that overall survival favored the addition of darolutamide to ADT and docetaxel in all stratification subgroups,” says Ronald Tutrone, MD, FACS, CPI.
November 01, 2022
“This equation that is true for White men, where more discussion leads to more PSA testing, did not hold for racial minorities,” says Hanan Goldberg, MD, MSc.
October 31, 2022
Dr. Elterman discusses the findings of his recent study on the use of sacral neuromodulation to treat various conditions, which was presented at the NSAUA Annual Meeting.
October 28, 2022
“The biggest finding is that we are seeing a steady increase in women representation in the field of urology,” says Teresa L. Danforth, MD.
